CN1686317A - Ginkgo total lactone composition possessing nervo protection action - Google Patents

Ginkgo total lactone composition possessing nervo protection action Download PDF

Info

Publication number
CN1686317A
CN1686317A CN 200510046141 CN200510046141A CN1686317A CN 1686317 A CN1686317 A CN 1686317A CN 200510046141 CN200510046141 CN 200510046141 CN 200510046141 A CN200510046141 A CN 200510046141A CN 1686317 A CN1686317 A CN 1686317A
Authority
CN
China
Prior art keywords
total lactone
ginkgo total
lactone composition
ginkgo
ginkalide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510046141
Other languages
Chinese (zh)
Other versions
CN100569234C (en
Inventor
游松
郭军
杨莉
贾娴
张予阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Pharmaceutical University
Original Assignee
Shenyang Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Pharmaceutical University filed Critical Shenyang Pharmaceutical University
Priority to CNB2005100461418A priority Critical patent/CN100569234C/en
Publication of CN1686317A publication Critical patent/CN1686317A/en
Application granted granted Critical
Publication of CN100569234C publication Critical patent/CN100569234C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A gingko's general lactone composition with nerve-protecting function is prepared from gingko leaf and contains ginkalide A, B and C and bilobalide. It can be used to prepare the medicine in different forms for protecting nerve and treating the nerve degenerative or injury diseases (cerebral injury, senile dementia, etc).

Description

Ginkgo total lactone composition with neuroprotective
Technical field:
The present invention relates to medical technical field, exactly it is a kind of ginkgo total lactone composition with neuroprotective.
Background technology:
Semen Ginkgo is a Ginkgoaceae Ginkgo plant.The Ginkgo plant comes across the jurassic age before 100,017,000 years, and Semen Ginkgo is the seeds of present unique survival in the Ginkgo plant family, have the title of " living fossil ".Semen Ginkgo has history in 5000 as medicinal at least in China, and it is recorded in " legendary god of farming's BAICAO warp " the earliest.In Compendium of Material Medica, put down in writing Semen Ginkgo " its nature and flavor sweetness and bitterness and puckery; go into lung, kidney two warps; have that relieving asthma and cough, leukorrhagia stopping are turbid, the effect of urine reducing ", record Folium Ginkgo in " Bencao Pinhui Jingyao " " sweet-bitter flavor, puckery, property flat; return lung meridian; can astringe the lung relieving asthma, beneficial heart pain relieving, removing dampness stopping leak " (" China Dispensary " 1997,8 (2): 85-86).
Folium Ginkgo extract is the medical material of including under [item of Pharmacopoeia of the People's Republic of China version in 2000.Its active ingredient mainly contains flavonoid glycoside and Folium Ginkgo terpene lactones two classes.The Folium Ginkgo flavone glycoside mainly contains quercetin glycoside, kaempferol glycoside and bis-flavonoid.Ginkalide A, B, C and bilobalide be from Folium Ginkgo extract, carry altogether 4 main terpenoids.Gingko episperm also contains compositions (" Chinese wild plant resource " 1995 (1): 25 Sheng Soviet Unions such as ginkgoic acid, the inferior ginkgolic acid of hydrogenation, bilobol, Ginnol, asparagine, tannin, flavonoid, saccharide in addition, the chemical constituent of gingko episperm and with [J] " Chinese herbal medicine " 1995,26 (6): 29 Wang Jie, the separation of gingko episperm chemical constituent and evaluation [J]).
Along with deepening continuously of studying, modern study proves that the active component Ginkgo total lactones of Folium Ginkgo is different with the pharmacological action of this two compounds of ginkgetin glycoside in recent years:
Flavone compound is a ubiquitous class natural product in plant, and ginkgetin can obviously be regulated antiotasis, and expansion artery blood vessel, reduction blood vessel wall permeability increase the coronary blood liquid measure; Reduce myocardial oxygen consumption, strengthen the toleration of myocardial cell to hypoxic-ischemic, microcirculation improvement.Ginkgetin is a kind of free radical scavenger simultaneously, so defying age, antitumaous effect (" Chinese pharmacology communication " 2003,20 (2): 68) are arranged.
Ginkgo total lactone composition mainly comprises: ginkalide A, ginkalide B, ginkalide C and bilobalide, this is a class only exists, has special construction and remarkable pharmacologically active in Semen Ginkgo a unique natural product, so far do not find to be present in (" World Science technology-Chinese medicine modernization " 2003,5 (1): the research overview of 33-38 bilobalide) in other plant as yet.The more important thing is that they have unique pharmacological action and therapeutic value.The pharmacological action of Ginkgo total lactones is very extensive, and relevant report is existing a lot.When a large amount of Semen Ginkgo extrac (24% total flavonoid glycoside, 6% total lactone) preparations demonstrate clinically cardiovascular and cerebrovascular disease had excellent curative nervous system is also had certain curative effect, point out Ginkgo total lactones probably neuroprotective to be played main contribution with unique texture.Given this, be object of study with high-purity Semen Ginkgo total lactone composition (ginkalide A, B, C and content of bilobalide are 90%), from integral body to the molecular level, studied its neuroprotective.Experimental result proves; ginkgo total lactone composition can protect rat cortex neurocyte to avoid the infringement of glutamic acid excitatory toxicity; the neuroprotective cell is avoided the oxidative stress infringement of hydrogen peroxide-induced; pair cell lacks sugared anoxia infringement and has protective effect equally; ginkgo total lactone composition also can strengthen the expression of bcl-2 in rat fetus cortex neurocyte that has been weakened by oxygen-derived free radicals in addition, weakens the bax and the P that have been increased by oxygen-derived free radicals 53Expression, thereby bring into play the inductive apoptosis effect of its resistant activity oxygen-derived free radicals.
Summary of the invention:
The purpose of this invention is to provide a kind of ginkgo total lactone composition with neuroprotective.The indication ginkgo total lactone composition mainly contains ginkalide A, ginkalide B, ginkalide C and bilobalide.The content sum of ginkalide A, B, C and bilobalide is greater than 80%, less than 99% in the compositions.The bilobalide proportion is 20%-80% in the described compositions.Described compositions can be used for preparing the pharmaceutical preparation of various nerve degenerations of treatment or injury disease.Described composite preparation comprises special injection or infusion preparation, comprises slow release or controlled-release pharmaceutical formulation, comprises the coelenteron administration, spray delivery, Transdermal absorption or oral pharmaceutical preparation, comprise various folk prescriptions and compound medicinal formulation.
The preparation method of ginkgo total lactone composition of the present invention, its concrete characterization step is as follows:
(1) green drying Folium Ginkgo coarse powder gets extracting solution after the aqueous alcohol reflux, extract.
(2) concentrate or reclaim solvent and filtration, filtrate is removed water-solubility impurity through organic solvent extraction.
(3) extract is dissolved in the aqueous alcohol organic solvent extraction weeding of grease solubility impurity after concentrating.
(4) by polyamide column chromatography, water alcohol eluting concentrates the final vacuum drying.
(5) aqueous alcohol dissolving is filtered, and filtrate decompression concentrates, spraying or vacuum drying, pulverize above-mentioned ginkgo total lactone composition.
Advantage of the present invention is: the result proves by experiment; ginkgo total lactone composition can protect rat cortex neurocyte to avoid the infringement of glutamic acid excitatory toxicity; the neuroprotective cell is avoided the oxidative stress infringement of hydrogen peroxide-induced; pair cell lacks sugared anoxia infringement and has protective effect equally; ginkgo total lactone composition also can strengthen the expression of bcl-2 in rat fetus cortex neurocyte that has been weakened by oxygen-derived free radicals in addition, weakens the bax and the P that have been increased by oxygen-derived free radicals 53Expression, thereby bring into play the inductive apoptosis effect of its resistant activity oxygen-derived free radicals.Said composition is applicable to makes various folk prescription pharmaceutical preparatioies, can be made into slow release or controlled-release pharmaceutical formulation; Can be made into coelenteron administration, spray delivery, Transdermal absorption or oral pharmaceutical preparation; Can be made into ejection preparation or infusion preparation; Also can form compound medicinal formulation with other medicines (containing Chinese medicine extract or effective ingredient).Above pharmaceutical preparation has clear and definite neuroprotective, can be used for making the pharmaceutical preparation of various nerve degenerations of treatment or injury disease, for example is used for the treatment of apoplexy brain injury, senile dementia and multiple sclerosis etc.
Description of drawings:
Fig. 1 passes through HPLC testing result figure for compositions.
Fig. 2 is the RT-PCR testing result figure of ginkgo total lactone composition to the bcl-2 expression of cortex neurocyte.
Fig. 3 is the testing result figure of ginkgo total lactone composition to the RT-PCR of cortex neurocyte bax mRNA expression.
Fig. 4 is the testing result figure of ginkgo total lactone composition to the RT-PCR of cortex neurocyte p53 mRNA expression.
1. (8.058min) bilobalide among Fig. 1,2. (9.308min) bilobalide, 3. (17.692min) ginkalide A, 4. (20.092min) ginkalide B.
1 matched group that does not add any medicine among Fig. 2; 2. through H 2O 20.05mM and 0.1mM FeSO 43. of matched groups after the damaging processing add ginkgo total lactone composition 10 -2GL -1Matched group 4 through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds ginkgo total lactone composition 10 -3 GL -15 through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds ginkgo total lactone composition 10 -2GL -1.6. through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds Folium Ginkgo extract EGb76110 -2GL -1
1. matched groups that do not add any medicine among Fig. 3; 2. through H 2O 20.05mM and 0.1mM FeSO 4Matched group after the damaging processing; 3.. only add ginkgo total lactone composition 10 -2GL -1Matched group 4. through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds ginkgo total lactone composition 10 -3 GL -15 through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds ginkgo total lactone composition 10 -2GL -1.6. through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds Folium Ginkgo extract EGb76110 -2GL -16. through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds Folium Ginkgo extract EGb761 10 -2GL -1
1 through 8 hours H among Fig. 4 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds Folium Ginkgo extract EGb761 10 -2GL -1.2.. through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds ginkgo total lactone composition 10 -2 GL -13. through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Cell after the damaging processing adds ginkgo total lactone composition 10 -3 GL -14 add ginkgo total lactone composition 10 -2GL -1Matched group 5. through 8 hours H 2O 20.05mM and 0.1mM FeSO 4Matched group 6. after the damaging processing does not add the matched group of any medicine.
The specific embodiment:
The quantitative analysis of 1 compositions
1.1 described compositions detects (post: ODS by HPLC; Differential refraction detector; Mobile phase: methanol: water (35: 65) provides four peaks (seeing accompanying drawing 1), peak 1 (8.058min) is bilobalide (bilobalide), peak 2 (9.308min) is ginkalide C (ginkgolide C), (17.692min) draws liquid phase working standard curve (with concentration is abscissa, is vertical coordinate with the peak area) (seeing Table 1) for ginkalide A (ginkgolide A) peak 4 (20.092min) respectively for ginkalide B (ginkgolide B) 1.2 reference substances at peak 3
Table 1 ginkgo total lactone composition standard curve
Bilobalide The range of linearity (mg/ml) Regression equation Correlation coefficient r
Bilobalide ginkalide C ginkalide A ginkalide B ????0.206～2.060 ????0.056～0.560 ????0.150～1.500 ????0.102～1.020 ??Y＝1.622×10 5X-0.2021×10 4??Y＝1.558×10 5X-0.66×10 2??Y＝1.681×10 5X+3.461×10 3??Y＝1.7225×10 5X+7.22×10 2 ????0.9999 ????0.9998 ????0.9997 ????0.9996
Bilobalide and ginkgolectone AB C are the main terpenoid effective ingredient in the Folium Ginkgo extract, can be by specific technical process, and markization only contains the compositions of bilobalide and ginkgolectone AB C, and Ginkgo total lactones content is not less than 80% in the said composition.
The structure of 2 composition components is identified
Bilobalide
Sample: bilobalide
English name: Bilobalide
Molecular weight: 326
Molecular formula: C 15H 18O 8
Structural confirmation:
IR：3467.3，2962.6，1790.7，1364.3，865.4，792.0
MS：325.3(M-1)
1H-NMR：7.25(1H，d)，6.26(1H，s)，5.40(1H，s)，5.14(1H，d)，4.90(1H，t)，2.89(1H，d)，2.74(1H，d)，2.54(1H，m)，2.06(1H，m)，1.02(9H，s)
13C-NMR：176.9，173.2，172.7，98.9，85.2，82.4，67.8，64.9，57.3，41.1，36.7，35.3，26.1
Ginkalide A
Sample: Semen Ginkgo ester A
English name: Ginkgolide A
Molecular weight: 408
Molecular formula: C 20H 24O 9
Structural confirmation:
IR：3251.9，2962.6，1758.9，1137.9，963.0，798.2
MS：408(M)
1H-NMR: see Table 2
Table 2. bilobalide hydrogen spectrum data
The proton numbering Ginkalide A Ginkalide B Ginkalide C
?H-1?alpha ?H-1?beta ?H-2 ?H-6 ?H-7?alpha ?H-7?beta ?H-8 ?H-10?alpha ?H-12 ?H-14 ?t-Bu ?H-16 ????1.78(1H.dd) ????2.74(1H，q) ????4.82(1H，t) ????4.94(1H) ????2.03(1H，d) ????2.03(1H，d) ????1.70(1H，dd) ????4.92(1H) ????6.01(1H，s) ????2.92(1H，d) ????1.00(9H，s) ????1.09(3H，t) ????- ????4.03(1H，q) ????4.63(1H，d) ????5.29(1H，d) ????1.91(1H，m) ????2.13(1H，q) ????1.70(1H，q) ????4.91(1H，t) ????6.04(1H，d) ????2.83(1H，q) ????1.02(9H，s) ????1.09(3H，d) ????- ????3.69(1H，dd) ????4.33(1H，d) ????4.97(1H，d) ????3.76(1H，dddd) ????- ????1.25(1H，d) ????4.70(1H，d) ????5.80(1H，s) ????2.51(1H，q) ????0.80(9H，s) ????0.80(3H，t)
13C-NMR: see Table 3
Table 3. bilobalide carbon spectrum data
Bilobalide ????A ????B ????C
????C1 ????C2 ????C3 ????C4 ????36.2 ????85.2 ????68.2 ????100.3 ????73.3 ????91.4 ????82.3 ????98.0 ????74.6 ????92.6 ????83.5 ????98.9
????C5 ????C6 ????C7 ????C8 ????C9 ????C10 ????C11 ????C12 ????C13 ????C14 ????C15 ????C16 ????C17 ????C18，19，20 ????86.2 ????87.8 ????36.4 ????48.6 ????66.9 ????68.8 ????174.5 ????109.6 ????170.9 ????40.6 ????176.7 ????8.3 ????32.1 ????29.0 ????71.2 ????78.2 ????36.1 ????48.1 ????67.0 ????68.6 ????173.6 ????109.2 ????169.9 ????41.1 ????176.0 ????7.4 ????31.5 ????28.4 ????67.0 ????79.7 ????74.3 ????49.6 ????64.3 ????69.6 ????174.6 ????110.2 ????171.2 ????42.2 ????177.1 ????8.6 ????32.5 ????29.5
Ginkalide B
Sample: ginkalide B
English name: Ginkgolide B
Molecular weight: 424
Molecular formula: C 20H 24O 10
Structural confirmation:
IR：3451.9，2970.3，1780.4，1622.1，946.1，884.1
MS：424(M)
1H-NMR: see Table 2
13C-NMR: see Table 3
Ginkalide C
Sample: ginkalide C
English name: Ginkgolide C
Molecular weight: 440
Molecular formula: C 20H 24O 11
Structural confirmation:
IR：3430.3，2989.3，1785.4，1635.3，935.8，890.9
MS：440(M)
1H-NMR: see Table 2
13C-NMR: see Table 3
Conclusion: based on above analysis, and contrast document, with the literature value basically identical, can judge that four kinds of main components in this compositions are respectively bilobalide (Bilobalide), ginkalide A (Ginkgolide A), ginkalide B (Ginkgolide B), ginkalide C (Ginkgolide C).
3. the neuroprotective of this compositions
3.1 ginkgo total lactone composition is to the influence of the different damage models of rat cortex neurocyte of In vitro culture
3.2 ginkgo total lactone composition is to the influence of the rat cortex neurocyte of cultivation
(1) animal model: the rat cortex neurocyte of In vitro culture
(2) detect index: A 570, the active mensuration of lactic acid dehydrogenase (LDH).
(3) test section the results are shown in Table 4, shown in the table 5:
Table 4 in the normal cortex neurocyte of rat ginkgo total lactone composition to A 570Influence
????A 570
6 hours 12 hours 24 hours
Matched group TG 10 -1????TG?10 -2????TG?10 -3????TG?10 -4 ??0.179±0.013 ??0.182±0.019 ??0.186±0.018 ??0.185±0.019 ??0.181±0.014 ??0.158±0.015 △????0.161±0.012 ??0.168±0.020 ??0.163±0.017 ??0.160±0.015 ??0.143±0.013 △????0.157±0.011 **??0.153±0.016 *??0.150±0.014 ??0.148±0.013
. annotate: X ± s, n=6, (6h) compares with matched group △P＜0.05; With matched group (24h). compare *P＜0.05 or *P＜0.01
Table 5 ginkgo total lactone composition is to because the protective effect of the injured nerve cell that low serum causes
??LDH(U?L -1)
6 hours 12 hours 24 hours
Matched group TG 10 -1????TG?10 -2????TG?10 -3????TG?10 -4 ????38.5±1.76 ????37.3±1.75 ????38.3±1.21 ????39.0±4.82 ????38.0±1.79 ?43.8±1.64 △△??39.6±2.02 ★★??40.8±1.87 ★??41.2±1.98 ★??43.8±1.60 ????46.6±2.17 △△????????38.1±1.00 **????40.0±1.26 **????45.2±2.93 ????47.0±5.08
. annotate: X ± s, n=6, (6h) compares with matched group △ △P＜0.01; With matched group (12h). compare ★P＜0.05, *P＜0.01; With matched group (2 4h). compare ★ ★P＜0.01.
When cell changes low serum culture fluid into, A 570Prolongation in time and descending to some extent gradually, show that viable count reduces to some extent, because have only the Intramitochondrial succinate dehydrogenase of living cells just can make xanchromatic MTT reduce empurpled Jia Keli, but after adding ginkgo total lactone composition, the decline of this cell viability obviously makes moderate progress, when 24h, the increase effect of ginkgo total lactone composition pair cell vigor, within the specific limits, with the increase effect reinforcement of its concentration, ginkgo total lactone composition 10 -1With 10 -2GL -1The improvement effect particularly evident, this result is consistent with the measurement result of MTT, the results are shown in Table 4.
By table 5 as seen, cell is along with the prolongation with low serum culture fluid incubation time, the LDH that is released in the culture fluid increases, 12h and 24h matched group and 6h matched group relatively, the LDH activity has significant increase trend, at one time in, along with the increase that adds ginkgo total lactone composition concentration, can reduce the release of LDH significantly, the damage of expression ginkgo total lactone composition pair cell has dosage to rely on ground improvement effect, especially with ginkgo total lactone composition 10 -1With 10 -2GL -1Effect more obvious.
4.1 ginkgo total lactone composition is to the protective effect of cortex neural cell injury due to the glutamic acid
(1) animal model: the rat cortex neurocyte with the glutamic acid processing of In vitro culture.
(2) detect index: cell viability, the active mensuration of lactic acid dehydrogenase (LDH).
(4) test section the results are shown in Table shown in 6:
Table 6 ginkgo total lactone composition is to the protective effect of cortex neural cell injury due to the glutamic acid
Cell viability ????LDH(U·L -1)
Cell is handled 12h matched group glutamic acid (1mM) with 1mM glutamic acid a(1) glutamic acid (1mM) a+ ginkgo total lactone composition (10 -5g·L -1) bGinkgo total lactone composition (10 -4g·L -1) bGinkgo total lactone composition (10 -3g·L -1) bGinkgo total lactone composition (10 -2g·L -1) bGinkgo total lactone composition (10 -1g·L -1) bNimodipine (24 μ M) bNimodipine (48 μ M) b ????100.0±0.78 ????83.6±0.3## ? ????91.9±1.9* ????94.7±2.1* ????9?7.4±4.5** ????99.9±1.5** ????102.2±1.0** ????9?6.8±3.9** ????99.2±1.3** ????38.11±1.25 ????41.96±2.44## ????40.75±1.70 ????40.19±1.23 ????39.70±1.02 ????38.42±1.94* ????38.09±1.57** ????38.62±1.86* ????38.05±1.17**
Pretreatment (12h)
Matched group 100.0 ± 2.9 34.84 ± 1.79
Glutamic acid (1mM) c(2) 87.6 ± 3.3## 38.18 ± 2.16#
Glutamic acid (1mM) c+
Ginkgo total lactone composition (10 -5GL -1) d84.7 ± 1.5 38.04 ± 1.84
Ginkgo total lactone composition (10 -4GL -1) d90.8 ± 4.5 37.80 ± 2.02
Ginkgo total lactone composition (10 -3GL -1) d97.6 ± 2.0* 37.27 ± 2.46
Ginkgo total lactone composition (10 -2GL -1) d99.7 ± 0.3** 35.37 ± 1.41
Ginkgo total lactone composition (10 -1GL -1) d103.7 ± 1.3** 33.64 ± 1.24**
Nimodipine (24 μ M) d100.1 ± 2.2** 34.62 ± 1.59*
Nimodipine (48 μ M) d103.8 ± 1.2** 33.94 ± 1.35**
To annotate: X ± s (n=6). two groups of handling of matched group ##p＜0.01 * glutamic acid are respectively p＜0.05, and * * p＜0.01 shows between matched group and the glutamic acid group and there are differences
By table 6 as seen, cell is handled 12h with 1mM glutamic acid, uses ginkgo total lactone composition simultaneously and can obviously improve this infringement due to the glutamic acid.In addition, before handling cell with glutamic acid, use ginkgo total lactone composition and cell incubation 12h in advance, also visible medicine has significant protective effect, and is the concentration dependence.
4.2 ginkgo total lactone composition is to the protective effect of cortex neural cell injury due to the hydrogen peroxide
(1) animal model: the rat cortex neurocyte of the usefulness hydrogen peroxide treatment of In vitro culture.
(2) detect index: cell viability, the active mensuration of lactic acid dehydrogenase (LDH).
(3) test section the results are shown in Table shown in 7:
Table 7 ginkgo total lactone composition is to the protective effect of cortex neural cell injury due to the hydrogen peroxide
Cell viability LDH (UL -1)
Add H simultaneously 2O 2
Matched group 100 ± 1.2 35.12 ± 2.26
H 2O 2(0.2mM) a(1)??????????????81.4±1.1##???????38.90±2.53#
H 2O 2(0.2mM) a+
Ginkgo total lactone composition (10 -5GL -1) b86.0 ± 1.4 38.85 ± 1.70
Ginkgo total lactone composition (10 -4GL -1) b83.9 ± 0.8 38.77 ± 1.23
Ginkgo total lactone composition (10 -3GL -1) b85.8 ± 1.0 37.06 ± 1.57
Ginkgo total lactone composition (10 -2G L -1) b86.1 ± 2.5 37.78 ± 2.03
Ginkgo total lactone composition (10 -1GL -1) b82.6 ± 1.6 36.68 ± 1.71
Nimodipine (24 μ M) b89.7 ± 1.6 38.69 ± 1.82
Nimodipine (48 μ M) b92.1 ± 2.0* 35.73 ± 1.47*
Pretreatment (12h)
Matched group 100.0 ± 3.1 35.87 ± 2.72
H 2O 2(0.2mM) c(2)???????????????????80.7±1.4##????47.19±2.37##
H 2O 2(0.2mM) c+
Ginkgo total lactone composition (10 -5GL -1) d80.3 ± 0.7 48.26 ± 2.15
Ginkgo total lactone composition (10 -4GL -1) d78.8 ± 1.2 46.31 ± 2.45
Ginkgo total lactone composition (10 -3GL -1) d82.6 ± 0.5 45.45 ± 1.64
Ginkgo total lactone composition (10 -2GL -1) d90.3 ± 1.2* 43.10 ± 2.72*
Ginkgo total lactone composition (10 -1GL -1) d95.4 ± 0.5** 38.20 ± 1.54**
Nimodipine (24 μ M) d91.8 ± 1.9* 42.64 ± 2.91*
Nimodipine (48 μ M) d98.2 ± 1.7** 37.86 ± 1.97**
Annotate X ± s (n=6) matched group #p＜0.05##p＜0.01*H 2O 2Two groups that handle are respectively p＜0.05, * * p＜0.01
By table 7 as seen, the hydrogen peroxide of 0.2mM can obviously reduce cell viability, and can increase the release of the LDH in the culture medium, shows the obvious damaging action of pair cell.With ginkgo total lactone composition in advance with cell incubation 12h, medicine can obviously improve the damaging action of hydrogen peroxide pair cell, its valid density is 10 -1With 10 -2GL -1, and, then do not see obvious influence with ginkgo total lactone composition and hydrogen peroxide while and cell incubation, the pre-clothes of prompting ginkgo total lactone composition can be protected the oxidative stress damage of hydrogen peroxide to neurocyte effectively.
4.3 the ginkgo total lactone composition pair cell lacks the protective effect of sugared anoxia infringement
(1) animal model: the rat cortex neurocyte of the scarce sugar of In vitro culture and anoxic treatment.
(2) detect index: cell viability, the active mensuration of lactic acid dehydrogenase (LDH).
(3) test section the results are shown in Table shown in 8:
Table 8 ginkgo total lactone composition pair cell lacks the protective effect of sugared anoxia infringement
Cell viability LDH (UL -1)
Matched group 100.0 ± 0.5 38.98 ± 1.61
Que Yang ﹠amp; Lack sugar a79.5 ± 0.6## 41.81 ± 1.9#
Que Yang ﹠amp; Lack sugar a+ +
Ginkgo total lactone composition (10 -5GL -1) b79.0 ± 0.6 41.39 ± 2.66
Ginkgo total lactone composition (10 -4GL -1) b80.4 ± 1.1 40.50 ± 1.77
Ginkgo total lactone composition (10 -3GL -1) b81.2 ± 2.2 39.29 ± 2.24
Ginkgo total lactone composition (10 -2GL -1) b81.4 ± 0.3 39.76 ± 1.98
Ginkgo total lactone composition (10 -1GL -1) b82.1 ± 1.3 39.24 ± 2.81
Nimodipine (24 μ M) b80.6 ± 1.8 40.38 ± 2.65
Nimodipine (48 μ M) b83.6 ± 2.4 40.61 ± 1.93
Annotate: X ± s (n=6) matched group #p＜0.05, ##p＜0.011 shows matched group and H 2O 2There are differences between the group
When lacking necessary nutrient substance in the culture fluid of neurocyte,, can think a kind of external model that is similar to the cell " ischemia " of integral experiment as lacking sugar and anoxia.This experimental result shows that behind cell " ischemia " 4h, cell viability significantly reduces, and can be reduced to 79.5 ± 0.6 by 100.0 ± 0.5 of matched group.When before " ischemia " handled, anticipating cell 12h, find that the pair cell vigor does not have obvious influence with ginkgo total lactone composition.The measurement result of LDH shows that also when " ischemia ", the LDH in the cell culture fluid leaks to wherein through cell membrane and raises, but the LDH in the pretreated cell culture fluid of ginkgo total lactone composition does not have obvious minimizing, the results are shown in Table 8.
In a word; experimental result proves; ginkgo total lactone composition can protect rat cortex neurocyte to avoid the infringement of glutamic acid excitatory toxicity, and the neuroprotective cell is avoided the oxidative stress infringement of hydrogen peroxide-induced, and pair cell lacks sugared anoxia infringement and has protective effect equally.
5. ginkgo total lactone composition is to cultivating rat cortex cell bcl-2, the influence that bax and p53mRNA express
5.1 the influence that ginkgo total lactone composition is expressed rat cortex cell bcl-2 mRNA
(1) animal model: In vitro culture through H 2O 2And FeSO 4The rat cortex cell of damaging processing.
(2) detect index: (the mensuration of the gray level ratio of band of β-actin) of gene band to be checked and internal standard gene on the 1% gelose gel electrophoresis.
(3) test section the results are shown in shown in the accompanying drawing 2:
PCR result shows that matched group bcl-2 mRNA content is higher, and the cell of model group is through H 2O 20.05mM and 0.1mM FeSO 4After the damaging processing, the apparent in view minimizing of the expression of its bcl-2 mRNA and matched group, and the ginkgo total lactone composition of visible variable concentrations all can increase the expression of this gene in cortex cell after ginkgo total lactone composition is handled, and be dose-dependence (seeing accompanying drawing 2), EGb761 also has similar effect.In addition, be also shown in ginkgo total lactone composition itself Normocellular bcl-2 is expressed basically not influence.
5.2 the influence that the ginkgo total lactone composition of variable concentrations is expressed bax mRNA in the cortex cell
(1) animal model: In vitro culture through H 2O 2And FeSO 4The rat cortex cell of damaging processing.
(2) detect index: (the mensuration of the gray level ratio of band of β-actin) of gene band to be checked and internal standard gene on the 1% gelose gel electrophoresis.
(3) test section the results are shown in shown in the accompanying drawing 3
The PCR experimental result shows that the model group cell is through H 2O 20.05mM and 0.1mM FeSO 4After the damaging processing, the expression of its bax mRNA is apparently higher than matched group, and at H 2O 20.05mM and 0.1mM FeSO 4In the cell that ginkgo total lactone composition is handled, this expression of gene no longer shows this unusual rising before the damaging processing, the increase of dosage and weaken (seeing accompanying drawing 3) gradually.The bax band that heavy dose of ginkgo total lactone composition is handled cell very a little less than, only slightly as seen.The effect that the bax that EGb761 also has reduction to be caused by oxygen-derived free radicals raises.Ginkgo total lactone composition itself is not expressed Normocellular bax and is changed.
5.3 the influence that p53 mRNA expresses in the ginkgo total lactone composition pair cell of variable concentrations
(1) animal model: In vitro culture through H 2O 2And FeSO 4The rat cortex cell of damaging processing.
(2) detect index: (the mensuration of the gray level ratio of band of β-actin) of gene band to be checked and internal standard gene on the 1% gelose gel electrophoresis.
(3) test section the results are shown in shown in the accompanying drawing 4
The PCR experimental result shows that the model group cell is through H 2O 20.05mM and 0.1mM FeSO 4After damage was handled, the expression of its p53 mRNA was apparently higher than matched group, and at H 2O 20.05mM and 0.1mM FeSO 4In the cell that ginkgo total lactone composition is handled, this expression of gene no longer shows this unusual rising before the damaging processing, recovers (seeing accompanying drawing 4) gradually with the increase of dosage, and heavy dose of ginkgo total lactone composition is to H 2O 20.05mM and 0.1mM FeSO 4The p53 of damaging processing cell expresses obviously and reduces, and compare P＜0.05 with the model group cell, and EGb761 does not show significantly this effect.Ginkgo total lactone composition is expressed Normocellular P53 and is not made significant difference.
In a word, bcl-2, bax and P 53All participate in the apoptosis regulation process of cell.The result shows, ginkgo total lactone composition can strengthen the expression of bcl-2 in rat fetus cortex neurocyte that has been weakened by oxygen-derived free radicals, weakens the bax and the P that have been increased by oxygen-derived free radicals 53Expression, thereby bring into play the inductive apoptosis effect of its resistant activity oxygen-derived free radicals.
Embodiment:
1. green drying Folium Ginkgo coarse powder 10Kg gets extracting solution after the aqueous alcohol reflux, extract.Concentrate or reclaim solvent and filtration, filtrate is removed water-solubility impurity through organic solvent extraction.Extract is dissolved in the aqueous alcohol organic solvent extraction weeding of grease solubility impurity after concentrating.Discard organic layer, pure water layer is concentrated vacuum drying.Aqueous alcohol dissolving is filtered, and filtrate decompression concentrates, spraying or vacuum drying, pulverize the described ginkgo total lactone composition 50g of claim 1.
2. get Ginkgo total lactones raw material 11g, add 50% propylene glycol solution 500ml and 45g sodium chloride, after-teeming is penetrated water to 5000ml, by the general operation process of injection.Every 5ml contains this compositions 10mg.In conjunction with symptom, prop up every day 1 time or follow the doctor's advice with 2-4 at every turn.
3. this compositions 2g ploughs pure 20g with dextran-40 or mountain and phosphoric acid buffer mixes in right amount, is used for the water for injection dissolving, by the general operation process of injection, and fill, lyophilizing is made every of freeze dried injection and is contained this compositions 0.02g.In conjunction with symptom, prop up with 1-3 at every turn, mix use, every day 1 time with transfusions such as injecting sodium chloride.
4. compositions 10g mixes with microcrystalline Cellulose 45g and magnesium stearate 5g, and mixture is used for beating sheet, every heavy 0.2g, and every contains this compositions 0.02g.In conjunction with symptom, obey the 1-2 sheet, every day 2-3 time at every turn.
5. this compositions 10g with corn starch 50g, adds water and makes soft material, crosses 12 mesh sieve pelletizes, and drying makes granule, incapsulates, and the heavy 0.2g of every capsules content contains this compositions 0.02g.In conjunction with symptom, obey the 1-2 sheet, every day 2-3 time or follow the doctor's advice at every turn.

Claims (6)

1, have the ginkgo total lactone composition of neuroprotective, it is characterized in that: the indication ginkgo total lactone composition mainly contains ginkalide A, ginkalide B, ginkalide C and bilobalide.
2, the ginkgo total lactone composition with neuroprotective according to claim 1 is characterized in that: the content sum of ginkalide A, B, C and bilobalide is greater than 80%, less than 99% in the compositions.
3, the ginkgo total lactone composition with neuroprotective according to claim 1 and 2 is characterized in that: the bilobalide proportion is 20%-80% in claim 1 and the 2 described compositionss.
4. as claim 1 or 2 or 3 described ginkgo total lactone compositions with neuroprotective, it is characterized in that: described compositions can be used for preparing the pharmaceutical preparation of various nerve degenerations of treatment or injury disease.
5, the ginkgo total lactone composition with neuroprotective according to claim 4 is characterized in that: described composite preparation comprises special injection or infusion preparation, comprises slow release or controlled-release pharmaceutical formulation, comprises the coelenteron administration, spray delivery, Transdermal absorption or oral pharmaceutical preparation, comprise various folk prescriptions and compound medicinal formulation.
6, a kind of preparation method that has the ginkgo total lactone composition of neuroprotective according to claim 1 is characterized in that:
(1) green drying Folium Ginkgo coarse powder gets extracting solution after the aqueous alcohol reflux, extract;
(2) concentrate or reclaim solvent and filtration, filtrate is removed water-solubility impurity through organic solvent extraction;
(3) extract is dissolved in the aqueous alcohol organic solvent extraction weeding of grease solubility impurity after concentrating;
(4) by polyamide column chromatography, water alcohol eluting concentrates the final vacuum drying;
(5) aqueous alcohol dissolving is filtered, and filtrate decompression concentrates, spraying or vacuum drying, pulverize claim 1 or 2 or 3 described ginkgo total lactone compositions.
CNB2005100461418A 2005-03-30 2005-03-30 Ginkgo total lactone composition with neuroprotective Expired - Fee Related CN100569234C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100461418A CN100569234C (en) 2005-03-30 2005-03-30 Ginkgo total lactone composition with neuroprotective

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100461418A CN100569234C (en) 2005-03-30 2005-03-30 Ginkgo total lactone composition with neuroprotective

Publications (2)

Publication Number Publication Date
CN1686317A true CN1686317A (en) 2005-10-26
CN100569234C CN100569234C (en) 2009-12-16

Family

ID=35304359

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100461418A Expired - Fee Related CN100569234C (en) 2005-03-30 2005-03-30 Ginkgo total lactone composition with neuroprotective

Country Status (1)

Country Link
CN (1) CN100569234C (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142532A (en) * 2011-12-06 2013-06-12 复旦大学 Ginkgolide osmotic pump tablet and preparation method thereof
WO2013159412A1 (en) * 2012-04-23 2013-10-31 成都百裕科技制药有限公司 Method for extracting and separating ginkgolides
CN104042607A (en) * 2014-05-27 2014-09-17 黑龙江珍宝岛药业股份有限公司 Pharmaceutical composition for the treatment of dementia and preparation method thereof
WO2019128499A1 (en) * 2017-12-29 2019-07-04 江苏康缘药业股份有限公司 Ginkgo diterpene lactone composition
WO2020207398A1 (en) * 2019-04-10 2020-10-15 成都百裕制药股份有限公司 Use of ginkgo terpene lactone in preparing drug for preventing and/or treating guillain-barré-strohl syndrome
CN111803487A (en) * 2019-04-10 2020-10-23 成都百裕制药股份有限公司 Application of ginkgolide in preparation of medicine for preventing and/or treating Guillain-Barre syndrome

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142532A (en) * 2011-12-06 2013-06-12 复旦大学 Ginkgolide osmotic pump tablet and preparation method thereof
CN103142532B (en) * 2011-12-06 2015-03-04 复旦大学 Ginkgolide osmotic pump tablet and preparation method thereof
WO2013159412A1 (en) * 2012-04-23 2013-10-31 成都百裕科技制药有限公司 Method for extracting and separating ginkgolides
US9084755B2 (en) 2012-04-23 2015-07-21 Chengdu Baiyu Technology Pharmacy Co., Ltd. Method for extracting and separating ginkgolides
CN104042607A (en) * 2014-05-27 2014-09-17 黑龙江珍宝岛药业股份有限公司 Pharmaceutical composition for the treatment of dementia and preparation method thereof
CN104042607B (en) * 2014-05-27 2016-06-29 黑龙江珍宝岛药业股份有限公司 For pharmaceutical composition treating dementia and preparation method thereof
WO2019128499A1 (en) * 2017-12-29 2019-07-04 江苏康缘药业股份有限公司 Ginkgo diterpene lactone composition
US11524041B2 (en) 2017-12-29 2022-12-13 Jiangsu Kanion Pharmaceutical Co., Ltd Ginkgo diterpene lactone composition
WO2020207398A1 (en) * 2019-04-10 2020-10-15 成都百裕制药股份有限公司 Use of ginkgo terpene lactone in preparing drug for preventing and/or treating guillain-barré-strohl syndrome
CN111803487A (en) * 2019-04-10 2020-10-23 成都百裕制药股份有限公司 Application of ginkgolide in preparation of medicine for preventing and/or treating Guillain-Barre syndrome
CN111803487B (en) * 2019-04-10 2022-12-02 成都百裕制药股份有限公司 Application of ginkgolide in preparation of medicine for preventing and/or treating Guillain-Barre syndrome

Also Published As

Publication number Publication date
CN100569234C (en) 2009-12-16

Similar Documents

Publication Publication Date Title
CN1154488C (en) Immuno inhibitort
CN1990484A (en) Silybin esters derivatives and preparation and use thereof
CN1772011A (en) Ginkgo leaf extract composition and its prepn
CN101040915A (en) Method for preparing a Shuanhuanglian injection and the component detecting method
CN1686317A (en) Ginkgo total lactone composition possessing nervo protection action
CN1708312A (en) New alpha-glucosidase inhibitors from a natural source
CN1902189A (en) Plant-origin beta3-adrenoceptor agonist and use of the same
CN101066292A (en) Clerodendranthus spiatus extract for treating urinary calculus and its prepn process
CN1568960A (en) High purity chlorogenic acid prescription
CN1915986A (en) High purified tanshinone IIA sodium sulfonate, fabricating method, and preparation
CN1174973C (en) Schizonepeta lactone and its extraction process and use
CN1911314A (en) Plant extractive and its prepn. method
CN1127950C (en) Antirheumatic agents
CN1861104A (en) Inula flower extractive used to breat diabets mellitus and hyperlipidemia
CN1528391A (en) Decoction preparation of semen sinapis albae, fructus perillae and semen raphani and its preparing method
CN1511583A (en) Chinese rose extract and its preparing method and use
CN1679648A (en) Mailuoning injection and its preparation and quality control
CN1803182A (en) Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof
CN1857588A (en) Quality control method for Xianlinggubao preparation
CN100350902C (en) Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan
CN101077341A (en) Application of aurantio-obtusifolin or its derivates in preparing hypolipidemic drug
CN1186026C (en) Application of hydroxyethyl puerarin in preparation of new medicine for curing cerebrovascular diseases
CN101077873A (en) Novel NEO-clerodane type diterpene compound and application thereof
CN1511535A (en) Use of spirosterol type steroid saponin in preparing medicine for treating cardio-cerebral vascular disease
CN1559420A (en) Medicne tablets with function of delaying senility, and prepn. method therefor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091216

Termination date: 20180330